Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20073887 | 1.00 | CHRM1 (0.44) | CHRM1OPRL1OPRM1OPRK1CYP3A4 | |
| SCHEMBL29709369 | 1.00 | CHRM1 (0.44) | CHRM1OPRL1OPRM1OPRK1CYP3A4 | |
| SCHEMBL20073894 | 0.90 | CHRM1 (0.46) | CHRM1OPRL1CHRM2CHRM5 | |
| SCHEMBL30179338 | 0.90 | CHRM1 (0.46) | CHRM1OPRL1CHRM2CHRM5 | |
| SCHEMBL23798589 | 0.89 | CHRM1 (0.43) | CHRM1OPRL1DRD2CHRM2CHRM5 | |
| SCHEMBL29709377 | 0.87 | OPRL1 (0.49) | CHRM1OPRL1OPRM1OPRK1 | |
| SCHEMBL20073889 | 0.87 | OPRL1 (0.49) | CHRM1OPRL1OPRM1OPRK1 | |
| SCHEMBL13640863 | 0.83 | OPRL1 (0.51) | CHRM1OPRL1OPRM1OPRK1DRD2 | |
| SCHEMBL20073879 | 0.82 | CHRM1 (0.45) | CHRM1OPRL1OPRM1OPRK1DRD2 | |
| SCHEMBL20073883 | 0.82 | CHRM1 (0.45) | CHRM1OPRL1OPRM1OPRK1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |